β-thalassemia intermedia: A clinical perspective

Cold Spring Harbor Perspectives in Medicine

Volumn 2, Issue 7, 2012, Pages

  Musallam, Khaled M ^a   Taher, Ali T ^b   Rachmilewitz, Eliezer A ^c  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^c WOLFSON MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CALCIFEDIOL; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HEMOGLOBIN BETA CHAIN; HEMOGLOBIN F; HEMOGLOBIN GAMMA CHAIN; HYDROXYUREA; LIPOCORTIN 5; REACTIVE OXYGEN METABOLITE; THROMBOSPONDIN; URIDINE DIPHOSPHATE GLUCOSE; ANTICOAGULANT AGENT; IRON; IRON CHELATING AGENT;

ALPHA THALASSEMIA; ANEMIA; ARTICLE; BETA THALASSEMIA; CELL ADHESION; CEREBROVASCULAR ACCIDENT; COGNITIVE DEFECT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ENDOCRINE DISEASE; GENETIC ASSOCIATION; HEMOGLOBIN SYNTHESIS; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYPERCOAGULABILITY; IRON CHELATION; IRON OVERLOAD; LEG ULCER; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; PATHOPHYSIOLOGY; PHENOTYPE; PULMONARY HYPERTENSION; QUALITY OF LIFE; SPLENECTOMY; STENOSIS; THALASSEMIA INTERMEDIA; THALASSEMIA MAJOR; THROMBOEMBOLISM; BLOOD TRANSFUSION; EXTRAMEDULLARY HEMATOPOIESIS; GENETICS; METABOLISM; REVIEW; RISK FACTOR; THROMBOPHILIA;

ANTICOAGULANTS; BETA-THALASSEMIA; BLOOD TRANSFUSION; ENDOCRINE SYSTEM DISEASES; HEMATOPOIESIS, EXTRAMEDULLARY; HUMANS; HYPERTENSION, PULMONARY; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; LEG ULCER; RISK FACTORS; SPLENECTOMY; THROMBOEMBOLISM; THROMBOPHILIA;

EID: 84867578130     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a013482     Document Type: Article

References (128)

1. Aessopos A, Farmakis D. 2005. Pulmonary hypertension in β-thalassemia. Ann NY Acad Sci 1054: 342-349.
2. Aessopos A, Stamatelos G, Skoumas V, Vassilopoulos G, Mantzourani M, Loukopoulos D. 1995. Pulmonary hypertension and right heart failure in patients with β-thalassemia intermedia. Chest 107: 50-53.
3. Aessopos A, Farmakis D, Karagiorga M, Voskaridou E, Loutradi A, HatziliamiA, Joussef J, Rombos J, Loukopoulos D. 2001. Cardiac involvement in thalassemia intermedia: A multicenter study. Blood 97: 3411-3416.
4. Aessopos A, Farmakis D, Deftereos S, Tsironi M, Tassiopoulos S, Moyssakis I, Karagiorga M. 2005. Thalassemia heart disease: A comparative evaluation of thalassemia major and thalassemia intermedia. Chest 127: 1523-1530.
5. Aessopos A, Kati M, Farmakis D. 2007. Heart disease in thalassemia intermedia: A review of the underlying pathophysiology. Haematologica 92: 658-665.
6. Aessopos A, Tsironi M, Andreopoulos A, Farmakis D. 2009. Heart disease in thalassemia intermedia. Hemoglobin 33: S170-S176.
7. al-Momen AK. 1991. Recombinant human erythropoietin induced rapid healing of a chronic leg ulcer in a patient with sickle cell disease. Acta Haematol 86: 46-48.
8. Amoozgar H, Farhani N, Karimi M. 2010. Risk factors for pulmonary hypertension in patients with thalassemia intermedia. Eur J Haematol 85: 549-551.
9. Amoozgar H, Farhani N, Karimi M. 2011a. Early echocardiographic findings in β-thalassemia intermedia patients using standard and tissue Doppler methods. Pediatr Cardiol 32: 154-159.
10. Amoozgar H, Farhani N, Khodadadi N, Karimi M, Cheriki S. 2011b. Comparative study of pulmonary circulation and myocardial function in patients with β-thalassemia intermedia with and without hydroxyurea, a case-control study. Eur J Haematol 87: 61-67.
11. Ataga KI, Cappellini MD, Rachmilewitz EA. 2007. β-Thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. Br J Haematol 139: 3-13.
12. Atichartakarn V, Angchaisuksiri P, Aryurachai K, Onpun S, Chuncharunee S, Thakkinstian A, Atamasirikul K. 2002. Relationship between hypercoagulable state and erythrocyte phosphatidylserine exposure in splenectomized haemoglobin E/β-thalassaemic patients. Br J Haematol 118: 893-898.
13. Atichartakarn V, Angchaisuksiri P, Aryurachai K, Chuncharunee S, Thakkinstian A. 2003a. In vivo platelet activation and hyperaggregation in hemoglobin E/β-thalassemia: A consequence of splenectomy. Int J Hematol 77: 299-303.
14. Atichartakarn V, Likittanasombat K, Chuncharunee S, Chandanamattha P, Worapongpaiboon S, Angchaisuksiri P, Aryurachai K. 2003b. Pulmonary arterial hypertension in previously splenectomized patients with β-thalassemic disorders. Int J Hematol 78: 139-145.
15. Au WY, Lam WW, Chu WW, Tam S, Wong WK, Lau J, Yeung YM, Liu HS, Liang R. 2009. Organ-specific hemosiderosis and functional correlation in Chinese patients with thalassemia intermedia and hemoglobin H disease. Ann Hematol 88: 947-950.
16. Auer JW, Berent R, Weber T, Eber B. 2002. Iron metabolism and development of atherosclerosis. Circulation 106: e7.
17. Balla J, Vercellotti GM, Nath K, Yachie A, Nagy E, Eaton JW, Balla G. 2003. Haem, haem oxygenase and ferritin in vascular endothelial cell injury. Nephrol Dial Transplant 18: v8-v12.
18. Borenstain-Ben Yashar V, Barenholz Y, Hy-Am E, Rachmilewitz EA, Eldor A. 1993. Phosphatidylserine in the outer leaflet of red blood cells from β-thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes. Am J Hematol 44: 63-65.
19. Borgna-Pignatti C. 2007. Modern treatment of thalassaemia intermedia. Br J Haematol 138: 291-304.
20. Borgna-Pignatti C, Carnelli V, Caruso V, Dore F, De Mattia D, Di Palma A, Di Gregorio F, Romeo MA, Longhi R, Mangiagli A, et al. 1998. Thromboembolic events in β thalassemia major: An Italian multicenter study. Acta Haematol 99: 76-79.
21. Borgna-Pignatti C, Rigon F, Merlo L, Chakrok R, Micciolo R, Perseu L, GalanelloR. 2003. Thalassemia minor, the Gilbert mutation, and the risk of gallstones. Haematologica 88: 1106-1109.
22. Borgna-Pignatti C, Vergine G, Lombardo T, Cappellini MD, Cianciulli P, MaggioA, Renda D, Lai ME, Mandas A, Forni G, et al. 2004. Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol 124: 114-117.
23. Borgna-Pignatti C, Marsella M, Zanforlin N. 2010. The natural history of thalassemia intermedia. Ann NY Acad Sci 1202: 214-220.
24. Brittenham G, Olivieri N. 2012. Cold Spring Harb Perspect Med (to be published).
25. Butthep P, Bunyaratvej A, Funahara Y, Kitaguchi H, Fucharoen S, Sato S, Bhamarapravati N. 1995. Alterations in vascular endothelial cell-related plasma proteins in thalassaemic patients and their correlation with clinical symptoms. Thromb Haemost 74: 1045-1049.
26. Butthep P, Bunyaratvej A, Funahara Y, Kitaguchi H, Fucharoen S, Sato S, Bhamarapravati N. 1997. Possible evidence of endothelial cell activation and disturbance in thalassemia: An in vitro study. Southeast Asian J Trop Med Public Health 28(Suppl): 141A-148A.
27. Camaschella C, Cappellini MD. 1995. Thalassemia intermedia. Haematologica 80: 58-68.
28. Cappellini MD, Robbiolo L, Bottasso BM, Coppola R, Fiorelli G, Mannucci AP. 2000. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol 111: 467-473.
29. Cappellini MD, Grespi E, Cassinerio E, Bignamini D, Fiorelli G. 2005. Coagulation and splenectomy: An overview. Ann NY Acad Sci 1054: 317-324.
30. Cappellini MD, Motta I, Musallam KM, Taher AT. 2010. Redefining thalassemia as a hypercoagulable state. Ann NY Acad Sci 1202: 231-236.
31. Chehal A, Aoun E, Koussa S, Skoury H, Taher A. 2003. Hypertransfusion: A successful method of treatment in thalassemia intermedia patients with spinal cord compression secondary to extramedullary hematopoiesis. Spine (Phila Pa 1976) 28: E245-E249.
32. Chen S, Eldor A, Barshtein G, Zhang S, Goldfarb A, Rachmilewitz E, Yedgar S. 1996. Enhanced aggregability of red blood cells of β-thalassemia major patients. Am J Physiol 270: H1951-H1956.
33. Cossu P, Toccafondi C, Vardeu F, Sanna G, Frau F, Lobrano R, Cornacchia G, Nucaro A, Bertolino F, Loi A, et al. 1981. Iron overload and desferrioxamine chelation therapy in β-thalassemia intermedia. Eur J Pediatr 137: 267-271.
34. Del Principe D, Menichelli A, Di Giulio S, De Matteis W, Cianciulli P, Papa G. 1993. PADGEM/GMP-140 expression on platelet membranes from homozygous β thalassaemic patients. Br J Haematol 84: 111-117.
35. Derchi G, Forni GL, Formisano F, Cappellini MD, Galanello R, D'Ascola G, BinaP, Magnano C, Lamagna M. 2005. Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica 90: 452-458.
36. Dettelbach HR, Aviado DM. 1985. Clinical pharmacology of pentoxifylline with special reference to its hemorrheologic effect for the treatment of intermittent claudication. J Clin Pharmacol 25: 8-26.
37. Eldor A, Rachmilewitz EA. 2002. The hypercoagulable state in thalassemia. Blood 99: 36-43.
38. Eldor A, Krausz Y, Atlan H, Snyder D, Goldfarb A, Hy-Am E, Rachmilewitz EA, Kotze HF, Heyns AD. 1989. Platelet survival in patients with β-thalassemia. Am J Hematol 32: 94-99.
39. Eldor A, Lellouche F, Goldfarb A, Rachmilewitz EA, Maclouf J. 1991. In vivo platelet activation in β-thalassemia major reflected by increased platelet-thromboxane urinary metabolites. Blood 77: 1749-1753.
40. Eldor A, Durst R, Hy-Am E, Goldfarb A, Gillis S, Rachmilewitz EA, Abramov A, MacLouf J, Godefray YC, De Raucourt E, et al. 1999. A chronic hypercoagulable state in patients with β-thalassaemia major is already present in childhood. Br J Haematol 107: 739-746.
41. Galanello R, Cao A. 1998. Relationship between genotype and phenotype. Thalassemia intermedia. Ann NY Acad Sci 850: 325-333.
42. Gardenghi S, Grady RW, Rivella S. 2010. Anemia, ineffective erythropoiesis, and hepcidin: Interacting factors in abnormal iron metabolism leading to iron overload in β-thalassemia. Hematol Oncol Clin North Am 24: 1089-1107.
43. Gillis S, Cappellini MD, Goldfarb A, Ciceri L, Fiorelli G, Rachmilewitz EA. 1999. Pulmonary thromboembolism in thalassemia intermedia patients. Haematologica 84: 959-960.
44. Gimmon Z, Wexler MR, Rachmilewitz EA. 1982. Juvenile leg ulceration in β-thalassemia major and intermedia. Plast Reconstr Surg 69: 320-325.
45. Glickstein H, El RB, Link G, Breuer W, Konijn AM, Hershko C, Nick H, Cabantchik ZI. 2006. Action of chelators in iron-loaded cardiac cells: Accessibility to intracellular labile iron and functional consequences. Blood 108: 3195-3203.
46. Goksel BK, Ozdogu H, Yildirim T, Oguzkurt L, Asma S. 2010. β-Thalassemia intermedia associated with moyamoya syndrome. J Clin Neurosci 17: 919-920.
47. Goldschmidt N, Spectre G, Brill A, Zelig O, Goldfarb A, Rachmilewitz E, VaronD. 2008. Increased platelet adhesion under flow conditions is induced by both thalassemic platelets and red blood cells. Thromb Haemost 100: 864-870.
48. Habib A, Kunzelmann C, Shamseddeen W, Zobairi F, Freyssinet JM, Taher A. 2008. Elevated levels of circulating procoagulant microparticles in patients with β-thalassemia intermedia. Haematologica 93: 941-942.
49. Hahalis G, Kalogeropoulos A, Terzis G, Tselepis AD, Kourakli A, Mylona P, Grapsas N, Alexopoulos D. 2011. Premature atherosclerosis in non-transfusion-dependent β-thalassemia intermedia. Cardiology 118: 159-163.
50. Haidar R, Mhaidli H, Taher AT. 2010. Paraspinal extramedullary hematopoiesis in patients with thalassemia intermedia. Eur Spine J 19: 871-878.
51. Helley D, Eldor A, Girot R, Ducrocq R, Guillin MC, Bezeaud A. 1996. Increased procoagulant activity of red blood cells from patients with homozygous sickle cell disease and β-thalassemia. Thromb Haemost 76: 322-327.
52. Hershko C, Graham G, Bates GW, Rachmilewitz EA. 1978. Non-specific serum iron in thalassaemia: An abnormal serum iron fraction of potential toxicity. Br J Haematol 40: 255-263.
53. Hovav T, Goldfarb A, Artmann G, Yedgar S, Barshtein G. 1999. Enhanced adherence of β-thalassaemic erythrocytes to endothelial cells. Br J Haematol 106: 178-181.
54. Iolascon A, Giordano P, Storelli S, Li HH, Coppola B, Piga A, Fantola E, Forni G, Cianciulli P, Perrotta S, et al. 2001. Thrombophilia in thalassemia major patients: Analysis of genetic predisposing factors. Haematologica 86: 1112-1113.
55. Isma'eel H, Chafic AH, Rassi FE, Inati A, Koussa S, Daher R, Gharzuddin W, Alam S, Taher A. 2008. Relation between iron-overload indices, cardiac echo-Doppler, and biochemical markers in thalassemia intermedia. Am J Cardiol 102: 363-367.
56. Jackson DV Jr., Randall ME, Richards F II. 1988. Spinal cord compression due to extramedullary hematopoiesis in thalassemia: Long-term follow-up after radiotherapy. Surg Neurol 29: 389-392.
57. Karimi M, Khanlari M, Rachmilewitz EA. 2008. Cerebrovascular accident in β-thalassemia major (β-TM) and β-thalassemia intermedia (β-TI). Am J Hematol 83: 77-79.
58. Karimi M, Bagheri H, Rastgu F, Rachmilewitz EA. 2010a. Magnetic resonance imaging to determine the incidence of brain ischaemia in patients with β-thalassaemia intermedia. Thromb Haemost 103: 989-993.
59. Karimi M, Cohan N, Moosavizadeh K, Falahi MJ, Haghpanah S. 2010b. Adverse effects of hydroxyurea in β-thalassemia intermedia patients: 10 years' experience. Pediatr Hematol Oncol 27: 205-211.
60. Karimi M, Mohammadi F, Behmanesh F, Samani SM, Borzouee M, Amoozgar H, Haghpanah S. 2010c. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with β-thalassemia intermedia. Eur J Haematol 84: 52-58.
61. Karimi M, Musallam KM, Cappellini MD, Daar S, El-Beshlawy A, Belhoul K, Saned MS, Temraz S, Koussa S, Taher AT. 2011. Risk factors for pulmonary hypertension in patients with β thalassemia intermedia. Eur J Intern Med 22: 607-610.
62. Kuypers FA, de Jong K. 2004. The role of phosphatidylserine in recognition and removal of erythrocytes. Cell Mol Biol (Noisy-le-grand) 50: 147-158.
63. Ladis V, Berdousi H, Gotsis E, Kattamis A. 2010. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia. Br J Haematol 151: 504-508.
64. Lai ME, Vacquer S, Carta MP, Spiga A, Cocco P, Angius F, Mandas A, Dessi S. 2011. Thalassemia intermedia is associated with a proatherogenic biochemical phenotype. Blood Cells Mol Dis 46: 294-299.
65. Littera R, La Nasa G, Derchi G, Cappellini MD, Chang CY, Contu L. 2002. Long-term treatment with sildenafil in a thalassemic patient with pulmonary hypertension. Blood 100: 1516-1517.
66. Lombardo T, Tamburino C, Bartoloni G, Morrone ML, Frontini V, Italia F, Cordaro S, Privitera A, Calvi V. 1995. Cardiac iron overload in thalassemic patients: An endomyocardial biopsy study. Ann Hematol 71: 135-141.
67. Malyutin Z, Shai E, Dana M, Rachmilewitz E, Fibach E, Varon D. 2012. Shorter carotid artery occlusion in a thalassemic mouse model: A potential role for oxidative stress affecting both RBCs and platelets. 17th European Haematology Association Congress, Amsterdam, The Netherlands, June 2012.
68. Mancuso A. 2010. Hepatocellular carcinoma in thalassemia: A critical review. World J Hepatol 2: 171-174.
69. Manfre L, Giarratano E, Maggio A, Banco A, Vaccaro G, Lagalla R. 1999. MR imaging of the brain: Findings in asymptomatic patients with thalassemia intermedia and sickle cell-thalassemia disease. AJR Am J Roentgenol 173: 1477-1480.
70. Marden FA, Putman CM, Grant JM, Greenberg J. 2008. Moyamoya disease associated with hemoglobin Fairfax and β-thalassemia. Pediatr Neurol 38: 130-132.
71. Mavrogeni S, Gotsis E, Ladis V, Berdousis E, Verganelakis D, Toulas P, Cokkinos DV. 2008. Magnetic resonance evaluation of liver and myocardial iron deposition in thalassemia intermedia and b-thalassemia major. Int J Cardiovasc Imaging 24: 849-854.
72. Melchiori L, Gardenghi S, Rivella S. 2010. β-Thalassemia: HiJAKing ineffective erythropoiesis and iron overload. Adv Hematol 2010: 938640.
73. Mokhtar GM, Adly AA, El Alfy MS, Tawfik LM, Khairy AT. 2010. N-terminal natriuretic peptide and ventilation-perfusion lung scan in sickle cell disease and thalassemia patients with pulmonary hypertension. Hemoglobin 34: 78-94.
74. Musallam KM, Taher AT. 2011. Thrombosis in thalassemia: Why are we so concerned? Hemoglobin 35: 503-510.
75. Musallam KM, Beydoun A, Hourani R, Nasreddine W, Raad R, Koussa S, TaherAT. 2011a. Brain magnetic resonance angiography in splenectomized adults with β-thalassemia intermedia. Eur J Haematol 87: 539-546.
76. Musallam KM, Cappellini MD, Wood JC, Motta I, Graziadei G, Tamim H, TaherAT. 2011b. Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia. Haematologica 96: 1605-1612.
77. Musallam KM, Khoury B, Abi-Habib R, Bazzi L, Succar J, Halawi R, Hankir A, Koussa S, Taher AT. 2011c. Health-related quality of life in adults with transfusion-independent thalassaemia intermedia compared to regularly transfused thalassaemia major: New insights. Eur J Haematol 87: 73-79.
78. Musallam KM, Taher AT, Duca L, Cesaretti C, Halawi R, Cappellini MD. 2011d. Levels of growth differentiation factor-15 are high and correlate with clinical severity in transfusion-independent patients with β thalassemia intermedia. Blood Cells Mol Dis 47: 232-234.
79. Musallam KM, Nasreddine W, Beydoun A, Hourani R, Hankir A, Koussa S, Haidar M, Taher AT. 2012a. Brain positron emission tomography in splenectomized adults with β-thalassemia intermedia: Uncovering yet another covert abnormality. Ann Hematol 91: 235-241.
80. Musallam KM, Sankaran VG, Cappellini MD, Duca L, Nathan DG, Taher AT. 2012b. Fetal hemoglobin levels and morbidity in untransfused patients with β-thalassemia intermedia. Blood 119: 364-367.
81. Napoli N, Carmina E, Bucchieri S, Sferrazza C, Rini GB, Di Fede G. 2006. Low serum levels of 25-hydroxy vitamin D in adults affected by thalassemia major or intermedia. Bone 38: 888-892.
82. Nassar AH, Usta IM, Taher AM. 2006. β-Thalassemia intermedia and pregnancy: Should we anticoagulate? J Thromb Haemost 4: 1413-1414.
83. Nassar AH, Naja M, Cesaretti C, Eprassi B, Cappellini MD, Taher A. 2008. Pregnancy outcome in patients with β-thalassemia intermedia at two tertiary care centers, in Beirut and Milan. Haematologica 93: 1586-1587.
84. Oberoi S, Bansal D, Singh P, Marwaha RK. 2010. Stroke in a young boy with β-thalassemia intermedia secondary to moyamoya syndrome. J Pediatr Hematol Oncol 32: 568-570.
85. Olivieri NF, Koren G, Matsui D, Liu PP, Blendis L, Cameron R, McClelland RA, Templeton DM. 1992. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood 79: 2741-2748.
86. Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G, Nemeth E. 2007. Liver iron concentrations and urinary hepcidin in β-thalassemia. Haematologica 92: 583-588.
87. Origa R, Barella S, Argiolas GM, Bina P, Agus A, Galanello R. 2008. No evidence of cardiac iron in 20 never-or minimally-transfused patients with thalassemia intermedia. Haematologica 93: 1095-1096.
88. Pakbaz Z, Fischer R, Fung E, Nielsen P, Harmatz P, Vichinsky E. 2007. Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients. Pediatr Blood Cancer 49: 329-332.
89. Panigrahi I, Dixit A, Arora S, Kabra M, Mahapatra M, Choudhry VP, Saxena R. 2005. Do α deletions influence hydroxyurea response in thalassemia intermedia?Hematology 10: 61-63.
90. Parent F, Bachir D, Inamo J, Lionnet F, Driss F, Loko G, Habibi A, Bennani S, Savale L, Adnot S, et al. 2011. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med 365: 44-53.
91. Phrommintikul A, Sukonthasarn A, Kanjanavanit R, Nawarawong W. 2006. Splenectomy: A strong risk factor for pulmonary hypertension in patients with thalassaemia. Heart 92: 1467-1472.
92. Pippard MJ, Weatherall DJ. 1988. Iron balance and the management of iron overload in β-thalassemia intermedia. Birth Defects Orig Artic Ser 23: 29-33.
93. Restivo Pantalone G, Renda D, Valenza F, D'Amato F, Vitrano A, Cassara F, Rigano P, Di Salvo V, Giangreco A, Bevacqua E, et al. 2010. Hepatocellular carcinoma in patients with thalassaemia syndromes: Clinical characteristics and outcome in a long term single centre experience. Br J Haematol 150: 245-247.
94. Rigano P, Pecoraro A, Calzolari R, Troia A, Acuto S, Renda D, Pantalone GR, Maggio A, Di Marzo R. 2010. Desensitization to hydroxycarbamide following long-term treatment of thalassaemia intermedia as observed in vivo and in primary erythroid cultures from treated patients. Br J Haematol 151: 509-515.
95. Roghi A, Cappellini MD, Wood JC, Musallam KM, Patrizia P, Fasulo MR, Cesaretti C, Taher AT. 2010. Absence of cardiac siderosis despite hepatic iron overload in Italian patients with thalassemia intermedia: An MRI T2* study. Ann Hematol 89: 585-589.
96. Ruf A, Pick M, Deutsch V, Patscheke H, Goldfarb A, Rachmilewitz EA, GuillinMC, Eldor A. 1997. In-vivo platelet activation correlates with red cell anionic phospholipid exposure in patients with β-thalassaemia major. Br J Haematol 98: 51-56.
97. Rund D, Rachmilewitz E. 2005. β-Thalassemia. N Engl J Med 353: 1135-1146.
98. Sanefuji M, Ohga S, Kira R, Yoshiura T, Torisu H, Hara T. 2006. Moyamoya syndrome in a splenectomized patient with β-thalassemia intermedia. J Child Neurol 21: 75-77.
99. Sankaran VG, Lettre G, Orkin SH, Hirschhorn JN. 2010. Modifier genes in Mendelian disorders: The example of hemoglobin disorders. Ann NY Acad Sci 1214: 47-56.
100. Singer ST, Kuypers FA, Styles L, Vichinsky EP, Foote D, Rosenfeld H. 2006. Pulmonary hypertension in thalassemia: Association with platelet activation and hypercoagulable state. Am J Hematol 81: 670-675.
101. Steinberg MH, Forget BG, Higgs DR, Weatherall DJ. 2009. Disorders of hemoglobin: Genetics, pathophysiology, and clinical management. Cambridge University Press, New York.
102. Sturgeon P, Itano HA, Bergren WR. 1955. Genetic and biochemical studies of intermediate types of Cooley's anaemia. Br J Haematol 1: 264-277.
103. Taher A, Isma'eel H, Cappellini MD. 2006a. Thalassemia intermedia: Revisited. Blood Cells Mol Dis 37: 12-20.
104. Taher A, Isma'eel H, Mehio G, Bignamini D, Kattamis A, Rachmilewitz EA, Cappellini MD. 2006b. Prevalence of thromboembolic events among 8, 860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost 96: 488-491.
105. Taher A, El Rassi F, Isma'eel H, Koussa S, Inati A, Cappellini MD. 2008a. Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia. Haematologica 93: 1584-1586.
106. Taher AT, Otrock ZK, Uthman I, Cappellini MD. 2008b. Thalassemia and hypercoagulability. Blood Rev 22: 283-292.
107. Taher A, Hershko C, Cappellini MD. 2009a. Iron overload in thalassaemia intermedia: Reassessment of iron chelation strategies. Br J Haematol 147: 634-640.
108. Taher A, Musallam KM, El Rassi F, Duca L, Inati A, Koussa S, Cappellini MD. 2009b. Levels of non-transferrin-bound iron as an index of iron overload in patients with thalassaemia intermedia. Br J Haematol 146: 569-572.
109. Taher AT, Musallam KM, El-Beshlawy A, Karimi M, Daar S, Belhoul K, Saned MS, Graziadei G, Cappellini MD. 2010a. Age-related complications in treatment-naive patients with thalassaemia intermedia. Br J Haematol 150: 486-489.
110. Taher AT, Musallam KM, Karimi M, El-Beshlawy A, Belhoul K, Daar S, Saned M, Cesaretti C, Cappellini MD. 2010b. Splenectomy and thrombosis: The case of thalassemia intermedia. J Thromb Haemost 8: 2152-2158.
111. Taher AT, Musallam KM, Karimi M, El-Beshlawy A, Belhoul K, Daar S, Saned MS, El-Chafic AH, Fasulo MR, Cappellini MD. 2010c. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: The OPTIMAL CARE study. Blood 115: 1886-1892.
112. Taher AT, Musallam KM, Nasreddine W, Hourani R, Inati A, Beydoun A. 2010d. Asymptomatic brain magnetic resonance imaging abnormalities in splenectomized adults with thalassemia intermedia. J Thromb Haemost 8: 54-59.
113. Taher AT, Musallam KM, Wood JC, Cappellini MD. 2010e. Magnetic resonance evaluation of hepatic and myocardial iron deposition in transfusion-independent thalassemia intermedia compared to regularly transfused thalassemia major patients. Am J Hematol 85: 288-290.
114. Taher AT, Musallam KM, Cappellini MD, Weatherall DJ. 2011. Optimal management of β thalassaemia intermedia. Br J Haematol 152: 512-523.
115. Tai SM, Chan JS, Ha SY, Young BW, Chan MS. 2006. Successful treatment of spinal cord compression secondary to extramedullary hematopoietic mass by hypertransfusion in a patient with thalassemia major. Pediatr Hematol Oncol 23: 317-321.
116. Tanno T, Miller JL. 2010. Iron loading and overloading due to ineffective erythropoiesis. Adv Hematol 2010: 358283.
117. Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, Moroney JW, Reed CH, Luban NL, Wang RH, et al. 2007. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 13: 1096-1101.
118. Tavazzi D, Duca L, Graziadei G, Comino A, Fiorelli G, Cappellini MD. 2001. Membrane-bound iron contributes to oxidative damage of β-thalassaemia intermedia erythrocytes. Br J Haematol 112: 48-50.
119. Thein SL. 2012. Molecular basis of β thalassemia. Cold Spring Harb Perspect Med doi: 10. 1101/cshperspect. a011700.
120. Voskaridou E, Douskou M, Terpos E, Papassotiriou I, Stamoulakatou A, Ourailidis A, Loutradi A, Loukopoulos D. 2004. Magnetic resonance imaging in the evaluation of iron overload in patients with β thalassaemia and sickle cell disease. Br J Haematol 126: 736-742.
121. Voskaridou E, Christoulas D, Antoniadou L, Terpos E. 2008. Continuous increase in erythropoietic activity despite the improvement in bone mineral density by zoledronic acid in patients with thalassemia intermedia-induced osteoporosis. Acta Haematol 119: 40-44.
122. Voskaridou E, Plata E, Douskou M, Papadakis M, Delaki EE, Christoulas D, Terpos E. 2010. Treatment with deferasirox (Exjade) effectively decreases iron burden in patients with thalassaemia intermedia: Results of a pilot study. Br J Haematol 148: 332-334.
123. Weatherall DJ. 2001. Phenotype-genotype relationships in monogenic disease: Lessons from the thalassaemias. Nat Rev Genet 2: 245-255.
124. Weatherall D. 2004. 2003 William Allan Award address. The thalassemias: The role of molecular genetics in an evolving global health problem. Am J Hum Genet 74: 385-392.
125. Weatherall DJ, Clegg JB. 2001. The thalassaemia syndromes. Blackwell Science, Oxford.
126. Weizer-Stern O, Adamsky K, Amariglio N, Rachmilewitz E, Breda L, Rivella S, Rechavi G. 2006. mRNA expression of iron regulatory genes in β-thalassemia intermedia and β-thalassemia major mouse models. Am J Hematol 81: 479-483.
127. Winichagoon P, Fucharoen S, Wasi P. 1981. Increased circulating platelet aggregates in thalassaemia. Southeast Asian J Trop Med Public Health 12: 556-560.
128. Zalloua PA, Shbaklo H, Mourad YA, Koussa S, Taher A. 2003. Incidence of thromboembolic events in Lebanese thalassemia intermedia patients. Thromb Haemost 89: 767-768.